Annual Drug Patent Expirations for KOMBIGLYZE+XR
Kombiglyze Xr is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.
KOMBIGLYZE XR drug price trends.
Drug patent litigation for KOMBIGLYZE XR.
This drug has one hundred and sixteen patent family members in forty-one countries.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. One supplier is listed for this compound. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
